Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognositc Factors in COVID-19 Patients Complicated With Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04272710
Recruitment Status : Withdrawn (Similar projects have been registered, and it need to be withdrawn.)
First Posted : February 17, 2020
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Dongying Zhang, Chongqing Medical University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

Condition or disease
2019-nCoV

Detailed Description:

At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.

Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.

A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
Actual Study Start Date : January 25, 2020
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Occupancy rate in the intensive care unit (ICU) [ Time Frame: up to 28 days ]
    The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.

  2. Mechanical Ventilation [ Time Frame: up to 28 days ]
    The number of patients requiring mechanical ventilation.

  3. Death [ Time Frame: up to 28 days ]
    The number of patients who died of 2019-nCoV infection.


Secondary Outcome Measures :
  1. All cause mortality [ Time Frame: up to 28 days ]
    The number of died 2019-nCoV infected patients from any cause.

  2. Time from onset of symptoms to main outcome and its components [ Time Frame: up to 28 days ]
    Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.

  3. Time to Clinical Recovery [ Time Frame: up to 28 days ]
    Time to Clinical Recovery


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China
Criteria

Inclusion Criteria:

  • Adult aged >=18years old;
  • Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
  • Diagnosed with primary hypertension.
  • Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.

Exclusion Criteria:

  • Near-death state (expected survival time less than 24 hours);
  • Malignant tumor;
  • Pregnancy or puerperium women;
  • ACEI contraindication
  • Patients who refused to participant.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04272710


Locations
Layout table for location information
China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Sponsors and Collaborators
Chongqing Medical University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dongying Zhang, Associate Professor, Chongqing Medical University
ClinicalTrials.gov Identifier: NCT04272710    
Other Study ID Numbers: 2020-02
First Posted: February 17, 2020    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Hypertension
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
 Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases